LA
CLDI icon

Linden Advisors’s Calidi Biotherapeutics CLDI Stock Holding History

Linden Advisors’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-417
Closed -$497K – 697
2022
Q2 		$497K Hold
417
– – ﹤0.01% 455
2022
Q1 		$495K Hold
417
– – ﹤0.01% 508
2021
Q4 		$492K Buy
+417
New +$491K ﹤0.01% 552

Other funds holding CLDI

DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
SFM
Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return
LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return

Linden Advisors's CLDI Position: Q3 2022 in Review

Linden Advisors sold out of Calidi Biotherapeutics (CLDI) in Q3 2022, closing a stake of 417 shares — an estimated $497K sold.

Linden Advisors first reported a position in CLDI in Q4 2021 and held it in 3 quarters. The position peaked at $497K in Q2 2022. 21 funds tracked by Wall St. Rank hold CLDI as of Q3 2022.

  • Linden Advisors reported no remaining Calidi Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • Linden Advisors sold 417 Calidi Biotherapeutics shares in Q3 2022, an estimated $497K.
  • Linden Advisors first reported a position in Calidi Biotherapeutics in Q4 2021 and held it in 3 quarters.
  • Linden Advisors's Calidi Biotherapeutics position peaked at $497K in Q2 2022.
  • 21 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2022.

Based on Linden Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.